Colchicine for Gout: Benefits and Risks

Primary Benefits

The American College of Physicians recommends colchicine as a second-line option for acute gout treatment, with low-dose colchicine (1.8 mg total over 1 hour) providing 50% or greater pain reduction with a number needed to treat (NNT) of 3-5, in patients with acute gout, compared to placebo 1, 2, 3
Colchicine is most effective when started within 12 hours of symptom onset, with significantly reduced effectiveness beyond 36 hours, in patients with acute gout 4

Colchicine is absolutely contraindicated in patients taking strong CYP3A4 inhibitors or P-glycoprotein inhibitors, especially if they have any degree of renal or hepatic impairment, due to increased risk of toxicity 1, 4
The most significant limitation of colchicine is that gastrointestinal side effects occur in up to 100% of patients using older high-dose regimens and in 23-26% using the recommended low-dose regimen, in patients with acute gout 1

The American College of Physicians recommends corticosteroids as first-line therapy for acute gout because they are generally safer and lower cost than colchicine, in patients with acute gout 1
The European League Against Rheumatism considers colchicine and NSAIDs equally effective, but notes colchicine causes severe diarrhea in most patients at high doses, in patients with acute gout 2, 3

The optimal dosing strategy for acute gout treatment is 1.2 mg at first sign of flare, followed by 0.6 mg one hour later, then 0.6 mg once or twice daily until attack resolves, in patients with acute gout 1, 4
For prophylaxis, 0.6 mg once or twice daily for at least 6 months when initiating urate-lowering therapy, in patients with gout 4, 5

Never use the obsolete high-dose regimen, never delay treatment beyond 36 hours of symptom onset, and never combine colchicine with strong CYP3A4 or P-glycoprotein inhibitors in patients with any renal or hepatic impairment, in patients with acute gout 1, 2, 4

Monitor CPK levels, especially in elderly patients and those with renal impairment, and watch for neuromuscular toxicity symptoms, in patients taking colchicine 6